Does Pretomanid Interact with Dabigatran Etexilate?
Pretomanid and Dabigatran Etexilate have a unknown drug interaction according to U.S. FDA drug labeling data. P-gp substrate. In vitro studies suggest pretomanid may inhibit P-gp, potentially increasing dabigatran etexilate exposure. Clinical impact unknown; monitor for adverse reactions. The mechanism involves potential p-gp transporter inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Unknown
- Pretomanid Class
- Antimycobacterial
- Management
- Consult your pharmacist
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Pretomanid and Dabigatran Etexilate occurs because potential p-gp transporter inhibition. Clinically, this means p-gp substrate. in vitro studies suggest pretomanid may inhibit p-gp, potentially increasing dabigatran etexilate exposure. clinical impact unknown; monitor for adverse reactions.
What To Tell Your Doctor or Pharmacist
If you are taking Pretomanid and your doctor is considering prescribing Dabigatran Etexilate (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Never stop or change either medication without first consulting your healthcare provider